Biogen
Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing therapies for neurological and neurodegenerative diseases, including multiple sclerosis and spinal muscular atrophy. The company is renowned for its pioneering products, such as Tecfidera and Spinraza, which have transformed treatment paradigms in their respective fields. Biogen's commitment to research and development has positioned it as a key player in the biotechnology industry, with notable achievements including the first approved treatment for spinal muscular atrophy. With a robust pipeline and a dedication to advancing science, Biogen continues to make significant contributions to patient care and the global healthcare landscape.
DitchCarbon Score
How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogen's score of 62 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biogen's reported carbon emissions
In 2023, Biogen reported total greenhouse gas (GHG) emissions of approximately 361,715 tonnes CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions accounted for about 57,611 tonnes CO2e, while Scope 2 emissions were approximately 31,059 tonnes CO2e. The majority of emissions stemmed from Scope 3, totalling around 304,105 tonnes CO2e, which includes emissions from purchased goods and services, capital goods, and employee commuting. Biogen has set ambitious climate commitments, aiming for net-zero GHG emissions across its entire value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 55% by 2032, using 2019 as the baseline year. Furthermore, Biogen plans to achieve a 100% reduction in these emissions by 2040. In addition, the company is committed to ensuring that 80% of its suppliers, based on spend, will have science-based targets by 2025. For Scope 3 emissions, Biogen aims for a 90% reduction by 2045. These initiatives reflect Biogen's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 60,179,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 187,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 262,358,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
